OUR COMPANY

 
  • 2012

    December

  • ENTRY INTO BIOPHARMA AS A DIVISION OF AGILA, THE SPECIALTY SUBSIDIARY OF STRIDES PHARMA
  • 2013

    October

  • RE-BRANDED AS STELIS BIOPHARMA AS A DIRECT SUBSIDIARY OF STRIDES
  • 2014

    May

  • SETS UP STATE-OF-ART R&D FACILITY IN BANGALORE
  • 2015

    March

  • GMS HOLDINGS MAKES A STRATEGIC INVESTMENT IN STELIS
  • 2015

    November

  • CONSTRUCTION OF INTEGRATED BIO MANUFACTURING FACILITY BEGINS
  • 2017

    April

  • OPENING OF PROCESS SCALE UP LAB IN COLLABORATION WITH MERCK LIFE SCIENCES
 
Pre-Clinical and Clinical Development
 
We offer services at every stage of the development life cycle from Pre-Clinical and Clinical Development to Commercial Supply. At Stelis BioSourceTM, we assure customers of CDMO/CMO services, our deep commitment to Quality, Service and Compliance. ​ We have made significant investments in setting up world-class infrastructure for R&D, Scale Up and cGMP commercial manufacturing with dedicated capacities for contract manufacturing. Importantly, we have built skilled teams in Manufacturing, Quality, Technology transfer with deep experience in handling biopharma operations in leading companies. Our stragegic location in Bangalore, India leverages the advantages of an emerging technological hub for R&D and next generation manufacturing. India is among the top 12 biotech destinations in the world and 3rd in Asia-Pacific after Japan and South Korea. India has the 2nd highest number of FDA approved facilities after USA and we are close to growth markets in ASEAN and MENA region.